Skip to main navigation
Skip to search
Skip to main content
University of Canberra Research Portal Home
Home
Profiles
Research output
Projects
Press/Media
Activities
Research units
Prizes
Student theses
Search by expertise, name or affiliation
The societal burden of haemophilia A. III – The potential impact of emicizumab on costs of haemophilia A in Australia
Laurie Brown
, Hai Anh La
,
Jinjing Li
, Matthias Brunner
, Martin Snoke
, Annette M Kerr
Research output
:
Contribution to journal
›
Article
›
peer-review
8
Citations (Scopus)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'The societal burden of haemophilia A. III – The potential impact of emicizumab on costs of haemophilia A in Australia'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Australia
100%
Potential Impact
100%
Hemophilia
100%
Societal Burden
100%
Emicizumab
100%
Societal Costs
30%
Indirect Costs
20%
Direct Costs
20%
First Year
10%
Treatment Costs
10%
Cost Impact
10%
Cost Reduction
10%
Pediatric
10%
Total Annual Cost
10%
Non-treatment
10%
Humanized
10%
Cost-based
10%
Bypassing Agents
10%
Blood Products
10%
Severe Haemophilia A
10%
Bispecific Antibody
10%
Factor IXa
10%
Bridging Factors
10%
Antibody Structure
10%
IgG4 Antibodies
10%
Immunology and Microbiology
Emicizumab
100%
Factor VIII
20%
Immunoglobulin G4
10%
Blood Product
10%
Bispecific Antibody
10%
Antibody Structure
10%
Agricultural and Biological Sciences
Factor VIII
100%